American Association for the Study of Liver Diseases An

A liver damaged by hepatitis C virus (HCV) can be replaced by transplantation, but HCV recurs universally and, unchecked, will damage the new liver as well. Study results show a new combination of direct-acting antivirals combined with ribavirin eradicated HCV for most transplant patients with recurrent HCV genotype 1 infection and liver damage.

Three strategies for achieving one-time screening for hepatitis C virus (HCV) show variable success, but all detected more cases of HCV than current practice.

Researchers from the Mayo Clinic recently reported, at the American Association for the Study of Liver Diseases (The Liver Meeting 2014), in Boston, MA, on the safety and efficacy in post-liver transplant of 2 new oral medications, simeprevir and sofosbuvir, within a 12-week treatment span.

A screening tool that uses a common marker for liver malignancy or inflammation in combination with other values holds promise for improved screening accuracy in hepatocellular carcinoma.

New combinations of direct-acting antivirals (DAAs) may point the way to hepatitis C virus (HCV) cures without ribavirin (RBV) for some patients.

As the rapidly evolving field of hepatitis C virus (HCV) treatment progresses, clinicians can look to an expanding array of clinical trials to guide and individualize treatment decisions.

Autoimmune hepatitis (AIH) represents a complex and heterogenous disease entity, with an increasing incidence for both genders and worldwide.

Outcomes for liver transplant recipients have never been better, and long-term survival will depend on a holistic approach that includes evidence-based health surveillance by hepatologists and others to optimize screening and primary prevention in this population.

Hepatorenal syndrome, a potentially deadly complication of ascites in liver disease that represents a devastating metabolic cascade of organ failure, should be recognized early and managed vigorously.